These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 25622064)
1. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. Avihingsanon A; Tongkobpetch S; Kerr SJ; Punyawudho B; Suphapeetiporn K; Gorowara M; Ruxrungtham K; Shotelersuk V J Acquir Immune Defic Syndr; 2015 May; 69(1):e36-7. PubMed ID: 25622064 [No Abstract] [Full Text] [Related]
2. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review. Culley CL; Kiang TK; Gilchrist SE; Ensom MH Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653 [TBL] [Abstract][Full Text] [Related]
3. Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia. Atrio JM; Sperling RS; Posada R; Rodriguez Caprio G; Chen KT J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e158-9. PubMed ID: 23970241 [No Abstract] [Full Text] [Related]
4. Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. Choe PG; Park WB; Song JS; Kim NH; Song KH; Park SW; Kim HB; Kim NJ; Oh MD J Korean Med Sci; 2010 Oct; 25(10):1427-30. PubMed ID: 20890421 [TBL] [Abstract][Full Text] [Related]
5. Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary. Bradbeer C; Ngwenya S; Baker P; George M Int J STD AIDS; 2012 Oct; 23(10):759. PubMed ID: 23104755 [No Abstract] [Full Text] [Related]
6. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. Eley T; Huang SP; Conradie F; Zorrilla CD; Josipovic D; Botes M; Osiyemi O; Hardy H; Bertz R; McGrath D AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1287-92. PubMed ID: 23782005 [TBL] [Abstract][Full Text] [Related]
7. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. East J; Blanton LS Antimicrob Agents Chemother; 2012 Feb; 56(2):1081-3. PubMed ID: 22123706 [TBL] [Abstract][Full Text] [Related]
8. Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients. Bissio E; Lopardo GD AIDS Res Hum Retroviruses; 2013 Mar; 29(3):415-7. PubMed ID: 23121190 [No Abstract] [Full Text] [Related]
9. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344 [TBL] [Abstract][Full Text] [Related]
10. Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study. Lopardo G; Bissio E; Espinola L; Gallego P; Stambullian M; Gadano A AIDS Res Hum Retroviruses; 2013 Mar; 29(3):456-60. PubMed ID: 23113663 [TBL] [Abstract][Full Text] [Related]
11. Severe atazanavir-associated hyperbilirubinemia revealing Canton G6PD deficiency in an Asian HIV-infected patient. Javelle E; Oliver M; Savini H; Aubry C; Badens C; Simon F AIDS; 2012 Jan; 26(2):249-51. PubMed ID: 22179231 [No Abstract] [Full Text] [Related]
12. Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms. Cicconi P; Bini T; Barassi A; Casana M; Turri O; Pateri F; Marchetti GC; Biondi ML; d'Eril GM; d'Arminio Manforte A J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e96-7. PubMed ID: 21317582 [No Abstract] [Full Text] [Related]
13. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Park WB; Choe PG; Song KH; Jeon JH; Park SW; Kim HB; Kim NJ; Oh MD; Choe KW Clin Infect Dis; 2010 Jul; 51(1):101-6. PubMed ID: 20504240 [TBL] [Abstract][Full Text] [Related]
14. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection]. Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617 [TBL] [Abstract][Full Text] [Related]
15. Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. Laprise C; Baril JG; Dufresne S; Trottier H AIDS Patient Care STDS; 2013 Jul; 27(7):378-86. PubMed ID: 23829329 [TBL] [Abstract][Full Text] [Related]
16. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Lankisch TO; Moebius U; Wehmeier M; Behrens G; Manns MP; Schmidt RE; Strassburg CP Hepatology; 2006 Nov; 44(5):1324-32. PubMed ID: 17058217 [TBL] [Abstract][Full Text] [Related]